Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle

Ultra-Rich Families Fuel $20 Billion Surge in Private Equity Buyouts

by Team Lumida
June 7, 2024
in Lifestyle
Reading Time: 3 mins read
A A
0
Ultra-Rich Families Fuel $20 Billion Surge in Private Equity Buyouts

Source: University of Pennsylvania

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. Ultra-rich families co-invested nearly $20 billion in buyouts this year.
  2. High borrowing costs push private equity firms to seek wealthy co-investors.
  3. Family offices increasingly allocate funds to private equity deals.

What Happened?

Ultra-rich families, with a combined worth exceeding $150 billion, have co-invested nearly $20 billion in private equity buyouts this year. Notable deals include Germany’s Viessmann family teaming up with KKR for a $3 billion acquisition and Michael Dell’s family office partnering with Silver Lake for a $13 billion buyout of Endeavor Group Holdings.

These families, spanning industries from children’s toys to household boilers, have become crucial capital sources for private equity firms like KKR & Co. and Silver Lake amid expensive borrowing conditions.

Why It Matters?

This trend underscores a significant shift in how private equity deals are financed. With pension funds and endowments hitting their allocation limits, buyout firms increasingly rely on wealthy families to fill the gap. This shift allows firms to reduce their own capital outlay, crucial at a time when high borrowing costs limit leverage.

Darren Allaway of Goldman Sachs noted a surge in engagement with private equity investors, signaling a continued trend. The involvement of ultra-rich families also highlights their growing sophistication in managing wealth, opening doors to potentially lucrative, long-term investment opportunities.

What’s Next?

Expect this trend to persist, with more family offices likely to increase their allocations to private equity. According to UBS Group AG, over a third of surveyed family office clients plan to boost investments in this sector. Major investment banks, recognizing this shift, are enhancing their services to cater to wealthy families.

As high borrowing costs continue to restrict traditional financing, the ultra-rich will become even more pivotal in driving private equity buyouts. Watch for continued collaboration between private equity firms and affluent families, potentially leading to more high-profile and lucrative deals.

Source: Business Standard
Tags: Family officesHigh borrowing costsprivate equityUltra-rich families
Previous Post

Nvidia Faces Record $34 Billion Short Bet

Next Post

Cash Upfront: How Miners Are Cashing In on Copper Shortage

Recommended For You

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
7 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
1 week ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
2 weeks ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Is Your Child’s Scholarship Taxable? The Rules Are More Complicated Than You Think — A Fall Planning Guide

by Team Lumida
2 weeks ago
group of people using laptop computer

With fall semester approaching, families need to understand that not all scholarship and financial aid dollars are created equal from a tax perspective — whether a scholarship is...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
3 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
3 weeks ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 weeks ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
4 weeks ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
1 month ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more
Next Post
Cash Upfront: How Miners Are Cashing In on Copper Shortage

Cash Upfront: How Miners Are Cashing In on Copper Shortage

Surprising Payroll Spike: Fed Rate Cuts Delayed Again?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

yellow and black road sign

Nuclear Startup to Build Reactor Plant at Manhattan Project Site

October 14, 2025
red and blue light streaks

Wall Street Wins Back M&A Debt from Private Credit

September 23, 2025
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

These AI Power Users Are Impressing Bosses and Leaving Co-Workers in the Dust

November 6, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018